INNOVENT BIO (01801.HK)'s total product revenue for 2024 amounted to more than RMB8.2 billion, representing a robust YoY growth of over 40%, according to INNOVENT BIO's announcement. In 4Q24, the ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

In America, heart disease is the No. 1 killer of men and women and the leading cause of death for people of most racial and ...

Researchers have found in Phase 3 LIBerate-HoFH trial that Lerodalcibep, a third-generation PCSK9 inhibitor, showed similar ...